Kelonia Therapeutics

in vivo CAR T Gene Therapy

Undisclosed programs RD hematologic cancers, undisclosed

Kelonia Therapeutics develops genetic medicines for a variety of diseases. They are developing a unique gene delivery approach that uses lentiviral vector-like particles to deliver genetic cargo to any desired target tissue. Their iGPS™ technology uses an engineered lentiviral vector particle with a targeting molecule that defines the iGPS particle’s specificity and an optimized fusogen that enables efficient delivery of therapeutic transgenes. Kelonia's initial focus is on developing therapies for solid tumors and hematologic cancers. Their goal is to bring genetic medicines to every patient in need.